Morning Market Gainers

shares climbed 17.85 percent to $4.95 after the company reported that it has been granted Orphan Drug Designation by the EMA for CF102 in the treatment of liver cancer.

gained 8.68 percent to $2.00 after the company reported preclinical data for its GEN-1 IL-12 immunotherapy in combination with avastin and doxil for ovarian cancer.

shares surged 6.57 percent to $19.96. Morgan Stanley upgraded Blue Buffalo Pet Products from Equal-weight to Overweight, while maintaining a price target of $24.

shares rose 6.49 percent to $26.58 following the discontinuation of Lilly's evacetrapib.

shares jumped 4.35 percent to $2.64 after surging 6.3 percent Friday on news of The Baupost Group having reported a 17.17 percent stake in the small-cap biopharmaceutical company.

shares rose 3.83 percent to $60.01 after the company reported positive phase 3 top-line data for investigational osteoporosis therapy abaloparatide at the ASBMR.

shares climbed 2.76 percent to $28.63 after Dell Inc agreed to buy EMC in a deal valued at around $67 billion. EMC reported Q3 preliminary EPS of $0.43 and revenue of $6.05 billion to $6.08 billion.